Drug-Target Information
Drug Name Target Name Drug Type Target Type Source Drug MeSHID Interaction Score Drug Status Target Action
canakinumab interleukin-1 beta biotech Successful target TTD , drugbank , DGIDB Rheumatoid Arthritis
Systemic Juvenile[MeSHID:C565798]
Muckle-Wells Syndrome[MeSHID:D056587]
Juvenile arthritis[MeSHID:D001171]
Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]
Vasculitis[MeSHID:D014657]
Urticaria[MeSHID:D014581]
Cryopyrin-Associated Periodic Syndromes[MeSHID:D056587]
Rheumatoid Arthritis[MeSHID:D001172]		 10.32 approved,investigational binder,inhibitor
canakinumab interleukin-1 beta biotech Successful target TTD , drugbank , DGIDB Rheumatoid Arthritis
Systemic Juvenile[MeSHID:C565798]
Muckle-Wells Syndrome[MeSHID:D056587]
Juvenile arthritis[MeSHID:D001171]
Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]
Vasculitis[MeSHID:D014657]
Urticaria[MeSHID:D014581]
Cryopyrin-Associated Periodic Syndromes[MeSHID:D056587]
Rheumatoid Arthritis[MeSHID:D001172]		 10.32 approved,investigational binder,antibody
canakinumab interleukin-1 beta biotech Successful target TTD , drugbank , DGIDB Rheumatoid Arthritis
Systemic Juvenile[MeSHID:C565798]
Muckle-Wells Syndrome[MeSHID:D056587]
Juvenile arthritis[MeSHID:D001171]
Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]
Vasculitis[MeSHID:D014657]
Urticaria[MeSHID:D014581]
Cryopyrin-Associated Periodic Syndromes[MeSHID:D056587]
Rheumatoid Arthritis[MeSHID:D001172]		 10.32 approved,investigational binder
click here to return to the previous page